Patient Support
CSL Behring has a long history of commitment to our patient communities. Some of the programs, resources, and support services for patients who rely on Zemaira® and their families are described below. Moreover, CSL Behring further serves the community through our outreach efforts.
Alpha-1 Guardian Program—A personal health management program that offers support, guidance and education for patients with Alpha-1. Learn more about how the Alpha-1 Guardian Program can benefit your patients.
CSL Behring AssuranceSM—Security for Your Patients
CSL Behring AssuranceSM is designed to enable patients who rely on Zemaira® to continue to receive this treatment even if they experience a lapse in their third-party, private health insurance. By providing complimentary Zemaira® to qualified patients in their time of need, we can offer an added level of security for people who rely on Alpha-1 therapy.
Anyone who uses Zemaira® and has third-party, private health insurance can enroll in CSL Behring AssuranceSM.* Once enrolled, patients earn a CSL Behring AssuranceSM Award Certificate for every 3 consecutive months they use Zemaira®. Each Certificate is worth a complimentary, 1-month supply of Zemaira® and can be redeemed in the event of a lapse in third-party, private health insurance.
For more information about CSL Behring AssuranceSM, visit www.CSLBehringAssurance.com.
Reimbursement Resource Center—For You and Your Patients
We make available a wide variety of third-party reimbursement services to healthcare providers and patients alike. These services include individual claim processing reviews, assistance in appeals, insurance investigations into product coverage, and prior approvals for therapies authorization.
The Reimbursement Answerline (1-800-676-4266) is available for individual case inquiries. For general information, visit our online Resource Center.
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.